The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the shift toward decentralized healthcare, Labcorp has launched an at-home colorectal cancer screening kit through its Labcorp OnDemand platform. This initiative aims to reduce barriers to preventive care for average-risk adults by providing a convenient, lab-backed alternative to initial clinical visits. According to reports, while the kit facilitates easier screening, it is designed as a collection tool and does not replace traditional colonoscopies.
This expansion places Labcorp in more direct competition with diagnostic peers like Exact Sciences (EXAS), whose Cologuard test generated over $600 million in revenue in the most recent quarter per company earnings reports (Search Citation). Labcorp is leveraging its vast laboratory infrastructure to capture share in the growing at-home diagnostics market, a sector seeing increased consumer demand. The company's stock, LH, stood at $284.39 per market data (close July 6, 2026).
At the close of July 6, 2026, LH was priced at $284.39, maintaining a steady position within its recent daily range of $282.58 to $287.04. Investors will be watching for the impact of these direct-to-consumer products on upcoming quarterly margins, particularly as broader market sentiment remains sensitive to economic indicators such as the U.S. Non-Farm Payrolls, which recently showed a lower-than-expected addition of 57,000 jobs.